


Emcure reduces price of weight management drug Poviztra by 55%

02 April 2026 | News

Price revision, effective April 3, 2026, will bring the innovator molecule within the reach of a significantly larger patient base across the country



Emcure Pharmaceuticals has announced the price revision of its weight management drug Poviztra® (semaglutide injection) across India. The reduced price would be starting at Rs 3,999/- per month (4 weekly doses). The innovator Semaglutide is available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg. It comes in a state-of-the-art pen device that provides the convenience of simple administration and precise dosing.

As the first Indian company to exclusively distribute and commercialise Poviztra®, a second brand of Novo Nordisk's semaglutide injection for obesity, Emcure aims to expand access and enable more patients to benefit from this proven therapy at the revised price.

The innovator biologic rDNA semaglutide molecule has been on the market for close to a decade. It is the most studied and used semaglutide globally with an equivalent of 49+ million patient years of exposure. It is backed by nearly 50 clinical trials in diverse clinical settings¹ and has been taken by millions of patients worldwide.